Novartis Pharms Corp Drug Patent Portfolio

Novartis Pharms Corp owns 2 orange book drugs protected by 19 US patents Given below is the list of Novartis Pharms Corp's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11058667 Sacubitril-valsartan dosage regimen for treating heart failure 09 May, 2036
Active
US9283209 Oral formulations of deferasirox 21 Nov, 2034
Active
US11135192 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
Active
US9517226 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
Active
US9937143 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
Active
US8877938 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 Nov, 2027
Active
US8877938 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 May, 2027
Active
US9388134 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 May, 2027
Active
US9388134 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 Nov, 2026
Active
US8101659 Methods of treatment and pharmaceutical composition 15 Jul, 2025
Active
US8101659 Methods of treatment and pharmaceutical composition 15 Jan, 2025
Active
US7468390 Methods of treatment and pharmaceutical composition 27 May, 2024 Expired
US7468390 Methods of treatment and pharmaceutical composition 27 Nov, 2023 Expired
US8404744 Methods of treatment and pharmaceutical composition 14 Jul, 2023 Expired
US8796331 Methods of treatment and pharmaceutical composition 14 Jul, 2023 Expired
US8404744 Methods of treatment and pharmaceutical composition 14 Jan, 2023 Expired
US8796331 Methods of treatment and pharmaceutical composition 14 Jan, 2023 Expired
US6465504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 05 Apr, 2019 Expired
US6596750 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 24 Jun, 2017 Expired


Given below is the list of recent legal activities going on the following drug patents of Novartis Pharms Corp.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 29 May, 2024 US9517226
Payment of Maintenance Fee, 8th Year, Large Entity 27 Dec, 2023 US9388134
Payment of Maintenance Fee, 8th Year, Large Entity 30 Aug, 2023 US9283209
Payment of Maintenance Fee, 12th Year, Large Entity 12 Jul, 2023 US8101659
Payment of Maintenance Fee, 8th Year, Large Entity 20 Apr, 2022 US8877938
Payment of Maintenance Fee, 8th Year, Large Entity 19 Jan, 2022 US8796331
Post Issue Communication - Certificate of Correction 18 Jan, 2022 US9937143
Post Issue Communication - Certificate of Correction 18 Jan, 2022 US9517226
Patent Issue Date Used in PTA Calculation 05 Oct, 2021 US11135192
Recordation of Patent Grant Mailed 05 Oct, 2021 US11135192
Payment of Maintenance Fee, 4th Year, Large Entity 22 Sep, 2021 US9937143
Email Notification 16 Sep, 2021 US11135192
Issue Notification Mailed 15 Sep, 2021 US11135192
Issue Fee Payment Verified 02 Sep, 2021 US11135192
Dispatch to FDC 02 Sep, 2021 US11135192


Novartis Pharms Corp's Drug Patent Litigations

Novartis Pharms Corp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 07, 2020, against patent number US8101659. The petitioner Biocon Pharma Limited, challenged the validity of this patent, with Novartis Pharmaceuticals Corporation as the respondent. Click below to track the latest information on how companies are challenging Novartis Pharms Corp's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8101659 August, 2020 Terminated-Denied
(16 Feb, 2021)
Novartis Pharmaceuticals Corporation Biocon Pharma Limited


Novartis Pharms Corp Drug Patents' Oppositions Filed in EPO

Novartis Pharms Corp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 21, 2008, by Mundipharma Gmbh. This opposition was filed on patent number EP03704413A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP13750725A Jan, 2022 STADA Arzneimittel AG Revoked
EP13750725A Jan, 2022 Generics [UK] Limited Revoked
EP13750725A Jan, 2022 Algemeen Octrooi- en Merkenbureau B.V. Revoked
EP13750725A Jan, 2022 Teva Pharmaceutical Industries Ltd Revoked
EP13750725A Jan, 2022 Wuesthoff & Wuesthoff Patentanwälte PartG mbB Revoked
EP13750725A Jan, 2022 Alfred E. Tiefenbacher (GmbH & Co. KG) Revoked
EP10176094A Apr, 2021 Krka, d.d., Novo mesto Granted and Under Opposition
EP10176094A Apr, 2021 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP10176094A Apr, 2021 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP10176094A Apr, 2021 betapharm Arzneimittel GmbH Granted and Under Opposition
EP10176094A Apr, 2021 D Young & Co LLP Granted and Under Opposition
EP10176094A Apr, 2021 STADA Arzneimittel AG Granted and Under Opposition
EP10176094A Apr, 2021 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Granted and Under Opposition
EP10176094A Jan, 2021 Generics [UK] Limited Granted and Under Opposition
EP14710654A Jul, 2019 INVOKAT Intellectual Property Services Patent maintained as amended
EP14710654A Jul, 2019 HGF Limited Patent maintained as amended
EP14710654A Jul, 2019 Teva Pharmaceutical Industries Ltd Patent maintained as amended
EP16188627A Sep, 2018 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP16188627A Sep, 2018 HGF Limited Granted and Under Opposition
EP06827689A Oct, 2014 Maiwald Patentanwalts GmbH Revoked
EP03704413A May, 2008 Mundipharma GmbH Opposition procedure closed


Novartis Pharms Corp's Family Patents

Novartis Pharms Corp drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 17.7% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Novartis Pharms Corp Drug List

Given below is the complete list of Novartis Pharms Corp's drugs and the patents protecting them.


1. Entresto

Entresto is protected by 16 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11058667 Sacubitril-valsartan dosage regimen for treating heart failure 09 May, 2036
(11 years from now)
Active
US11135192 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
(8 years from now)
Active
US9517226 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
(8 years from now)
Active
US9937143 Inhibitors for treating diseases characterized by atrial enlargement or remodeling 22 Aug, 2033
(8 years from now)
Active
US8877938
(Pediatric)
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 Nov, 2027
(3 years from now)
Active
US8877938 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 27 May, 2027
(2 years from now)
Active
US9388134
(Pediatric)
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 May, 2027
(2 years from now)
Active
US9388134 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations 08 Nov, 2026
(2 years from now)
Active
US8101659
(Pediatric)
Methods of treatment and pharmaceutical composition 15 Jul, 2025
(8 months from now)
Active
US8101659 Methods of treatment and pharmaceutical composition 15 Jan, 2025
(3 months from now)
Active
US7468390
(Pediatric)
Methods of treatment and pharmaceutical composition 27 May, 2024
(4 months ago)
Expired
US7468390 Methods of treatment and pharmaceutical composition 27 Nov, 2023
(10 months ago)
Expired
US8404744
(Pediatric)
Methods of treatment and pharmaceutical composition 14 Jul, 2023
(1 year, 3 months ago)
Expired
US8796331
(Pediatric)
Methods of treatment and pharmaceutical composition 14 Jul, 2023
(1 year, 3 months ago)
Expired
US8404744 Methods of treatment and pharmaceutical composition 14 Jan, 2023
(1 year, 8 months ago)
Expired
US8796331 Methods of treatment and pharmaceutical composition 14 Jan, 2023
(1 year, 8 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto's drug page


2. Jadenu

Jadenu is protected by 3 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9283209 Oral formulations of deferasirox 21 Nov, 2034
(10 years from now)
Active
US6465504 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 05 Apr, 2019
(5 years ago)
Expired
US6596750 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators 24 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List